$522 Million is the total value of NEXTHERA CAPITAL LP's 56 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHC | New | Bausch Health Cos Inc | $14,003,000 | – | 545,500 | +100.0% | 2.68% | – |
| ACAD | New | ACADIA Pharmaceuticals Inccall | $10,380,000 | – | 500,000 | +100.0% | 1.99% | – |
| ARQL | New | ArQule Inc | $9,834,000 | – | 1,737,397 | +100.0% | 1.88% | – |
| TXMD | New | TherapeuticsMD Inc | $8,575,000 | – | 1,307,100 | +100.0% | 1.64% | – |
| NKTR | New | Nektar Therapeutics | $7,803,000 | – | 128,000 | +100.0% | 1.50% | – |
| ACHN | New | Achillion Pharmaceuticals Inc | $5,829,000 | – | 1,583,954 | +100.0% | 1.12% | – |
| VKTX | New | Viking Therapeutics Inc | $5,709,000 | – | 327,730 | +100.0% | 1.09% | – |
| LLY | New | Eli Lilly & Coput | $5,366,000 | – | 50,000 | +100.0% | 1.03% | – |
| PFE | New | Pfizer Incput | $5,288,000 | – | 120,000 | +100.0% | 1.01% | – |
| INSM | New | Insmed Incput | $5,055,000 | – | 250,000 | +100.0% | 0.97% | – |
| FOMX | New | Foamix Pharmaceuticals Ltd | $4,282,000 | – | 747,308 | +100.0% | 0.82% | – |
| STRO | New | Sutro Biopharma Inc | $3,474,000 | – | 231,613 | +100.0% | 0.67% | – |
| IOVA | New | Iovance Biotherapeutics Inc | $3,336,000 | – | 296,500 | +100.0% | 0.64% | – |
| HRTX | New | Heron Therapeutics Inc | $2,844,000 | – | 89,849 | +100.0% | 0.54% | – |
| SESN | New | Sesen Bio Inc | $2,531,000 | – | 1,177,000 | +100.0% | 0.48% | – |
| CHMA | New | Chiasma Inc | $2,292,000 | – | 636,646 | +100.0% | 0.44% | – |
| OMED | New | OncoMed Pharmaceuticals Inc | $1,346,000 | – | 634,715 | +100.0% | 0.26% | – |
| SGYPQ | New | Synergy Pharmaceuticals Inc | $1,269,000 | – | 746,200 | +100.0% | 0.24% | – |
| CLSD | New | Clearside Biomedical Inc | $1,113,000 | – | 181,011 | +100.0% | 0.21% | – |
| SVRA | New | Savara Inc | $1,089,000 | – | 97,600 | +100.0% | 0.21% | – |
| PRQR | New | ProQR Therapeutics NV | $1,023,000 | – | 52,875 | +100.0% | 0.20% | – |
| ADAP | New | Adaptimmune Therapeutics Plcsponds adr | $1,005,000 | – | 74,132 | +100.0% | 0.19% | – |
| ACAD | New | ACADIA Pharmaceuticals Inc | $913,000 | – | 43,980 | +100.0% | 0.18% | – |
| MDGL | New | Madrigal Pharmaceuticals Inc | $857,000 | – | 4,000 | +100.0% | 0.16% | – |
| KERX | New | Keryx Biopharmaceuticals Inc | $680,000 | – | 200,000 | +100.0% | 0.13% | – |
| IMDZ | New | Immune Design Corp | $146,000 | – | 42,304 | +100.0% | 0.03% | – |
| VCNX | New | Vaccinex Inc | $124,000 | – | 17,047 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.